Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin Combined with CSII in Newly Diagnosed Type 2 Diabetes
NCT05677334Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The First Affiliated Hospital of Guangxi Medical University. Started Mar 2023; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05677334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677334.